Navigation Links
Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
Date:6/11/2009

CARY, N.C., June 11 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX) announced today that it will hold a special meeting of its stockholders on July 27, 2009. At the special meeting of stockholders, Cornerstone's stockholders will be asked to approve the issuance of and sale of shares of Cornerstone's common stock to Chiesi Farmaceutici SpA pursuant to the Stock Purchase Agreement, dated as of May 6, 2009, between Cornerstone and Chiesi Farmaceutici SpA.

Cornerstone's stockholders of record as of the close of business on June 25, 2009 will be entitled to notice of and to vote at the special meeting.

Cornerstone expects the closing contemplated by the stock purchase agreement to occur within two business days after its stockholders approve the stock sale.

About Cornerstone Therapeutics Inc.

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets. Cornerstone currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of Cornerstone's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of Cornerstone's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through Cornerstone's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of Cornerstone's currently marketed products, newly acquired products and product candidates.

Important Information

Cornerstone has filed a proxy statement and other documents regarding the transaction described in this press release with the Securities and Exchange Commission. Security holders are urged to read the proxy statement carefully because it contains important information about Cornerstone and the transaction with Chiesi Farmaceutici SpA. A definitive proxy statement will be sent to stockholders of Cornerstone seeking their approval of the transaction. Investors and security holders may obtain a free copy of the definitive proxy statement (when available) and other documents filed by Cornerstone with the SEC at the SEC's website at www.sec.gov or from Cornerstone's website at www.crtx.com. The definitive proxy statement (when available) and other relevant documents may also be obtained free of cost by directing a request to Cornerstone Therapeutics Inc., 1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518, attention: Chief Financial Officer.

Participants in Solicitation

Cornerstone and its directors, members of management and other employees may be deemed to be participants in the solicitation of proxies from the stockholders of Cornerstone in connection with the transaction. Information about Cornerstone and its directors and executive officers can be found in Cornerstone's proxy statement and Annual Report on Form 10-K for the year ended December 31, 2008 previously filed with the SEC. Additional information regarding the interests of those persons may be obtained by reading the proxy statement relating to the transaction.

    Investor Relations Contacts:
    FD
    Evan Smith/Brian Ritchie
    212-850-5600
    evan.smith@fd.com/brian.ritchie@fd.com
    Media Relations Contact:
    FD
    Robert Stanislaro
    212-850-5600
    robert.stanislaro@fd.com


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
3. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
4. Cornerstone Therapeutics Announces New Board of Directors
5. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
6. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
7. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Cornerstone Therapeutics Announces Management Change
10. TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 10, 2016 ... ... Programming (NLP) practitioner, is known locally for a series of therapeutic sessions to ... in-the-moment in their characters and in their lives. The series, known as “Mindfulness ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former ... takes a closer look at cases of TBI being managed by their members. The ... the aging population, and identifies the challenges associated with their care. , During the ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016 Intouch Solutions, a leading marketing ... industry-wide trend regarding the evolution of digital sales ... efficiently deliver compelling sales presentations via tablets. After ... in 2015, Intouch uncovered that while most pharmaceutical ... DSAs, many are not using them effectively during ...
(Date:2/10/2016)... Feb. 9, 2016 On Tuesday, ... (FDA) met with its Arthritis Advisory Committee ... of Johnson & Johnson,s Remicade and most ... in the U.S. The Biologics Prescribers Collaborative ... - Alliance for Patient Access, American Association ...
(Date:2/10/2016)... , February 10, 2016 The campaign aims ... 5 years reach the milestone of their 5 th ... ensure 2,50,532 children between the ages of 2 - ...   --> The campaign aims to ... years reach the milestone of their 5 th birthday   ...
Breaking Medicine Technology: